Any guesses on What will be required IYO in terms of LOGs for RNAi to be viable in a combo therapy if core inhibitor alone provides ~3-4 LOGs of reduction? Also, what IMO will be the third drug in a combo?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.